Indivior (NASDAQ:INDV - Get Free Report) is set to release its earnings data before the market opens on Thursday, April 25th. Analysts expect Indivior to post earnings of $0.38 per share for the quarter. Indivior has set its FY 2024 guidance at EPS.
Indivior (NASDAQ:INDV - Get Free Report) last announced its quarterly earnings results on Thursday, February 22nd. The company reported $0.43 earnings per share for the quarter, beating analysts' consensus estimates of $0.28 by $0.15. Indivior had a return on equity of 538.18% and a net margin of 0.18%. The firm had revenue of $293.00 million for the quarter, compared to analysts' expectations of $260.00 million. On average, analysts expect Indivior to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.
Indivior Stock Performance
NASDAQ:INDV traded down $0.50 during trading hours on Thursday, reaching $18.76. The company had a trading volume of 84,420 shares, compared to its average volume of 119,962. The stock has a 50-day moving average of $20.41 and a two-hundred day moving average of $18.42. Indivior has a one year low of $14.38 and a one year high of $26.50.
Analyst Upgrades and Downgrades
Separately, Craig Hallum started coverage on Indivior in a research report on Wednesday, April 3rd. They issued a "buy" rating and a $37.00 price target on the stock.
Read Our Latest Analysis on INDV
Institutional Trading of Indivior
Several large investors have recently made changes to their positions in INDV. Goldman Sachs Group Inc. bought a new stake in shares of Indivior during the second quarter worth $83,678,000. Barclays PLC grew its holdings in shares of Indivior by 746.6% during the fourth quarter. Barclays PLC now owns 3,093,161 shares of the company's stock worth $47,232,000 after purchasing an additional 2,727,791 shares during the last quarter. Deutsche Bank AG bought a new stake in shares of Indivior during the third quarter worth $3,181,000. Geode Capital Management LLC bought a new stake in shares of Indivior during the second quarter worth $2,510,000. Finally, Nuveen Asset Management LLC bought a new stake in shares of Indivior during the fourth quarter worth $1,488,000. Institutional investors own 60.33% of the company's stock.
Indivior Company Profile
(
Get Free Report)
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Featured Stories
Before you consider Indivior, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Indivior wasn't on the list.
While Indivior currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
